TY  - JOUR
A1  - Kan, Zhengyan
A1  - Zheng, Hancheng
A1  - Liu, Xiao
A1  - Li, Shuyu
A1  - Barber, Thomas D.
A1  - Gong, Zhuolin
A1  - Gao, Huan
A1  - Hao, Ke
A1  - Willard, Melinda D.
A1  - Xu, Jiangchun
A1  - Hauptschein, Robert
A1  - Rejto, Paul A.
A1  - Fernandez, Julio
A1  - Wang, Guan
A1  - Zhang, Qinghui
A1  - Wang, Bo
A1  - Chen, Ronghua
A1  - Wang, Jian
A1  - Lee, Nikki P.
A1  - Zhou, Wei
A1  - Lin, Zhao
A1  - Peng, Zhiyu
A1  - Yi, Kang
A1  - Chen, Shengpei
A1  - Li, Lin
A1  - Fan, Xiaomei
A1  - Yang, Jie
A1  - Ye, Rui
A1  - Ju, Jia
A1  - Wang, Kai
A1  - Estrella, Heather
A1  - Deng, Shibing
A1  - Wei, Ping
A1  - Qiu, Ming
A1  - Wulur, Isabella H.
A1  - Liu, Jiangang
A1  - Ehsani, Mariam E.
A1  - Zhang, Chunsheng
A1  - Loboda, Andrey
A1  - Sung, Wing Kin
A1  - Aggarwal, Amit
A1  - Poon, Ronnie T.
A1  - Fan, Sheung Tat
A1  - Wang, Jun
A1  - Hardwick, James
A1  - Reinhard, Christoph
A1  - Dai, Hongyue
A1  - Li, Yingrui
A1  - Luk, John M.
A1  - Mao, Mao
T1  - Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma
Y1  - 2013/09/01 
JF  - Genome Research 
JO  - Genome Research 
SP  - 1422 
EP  - 1433 
DO  - 10.1101/gr.154492.113 
VL  - 23 
IS  - 9 
UR  - http://genome.cshlp.org/content/23/9/1422.abstract 
N2  - Hepatocellular carcinoma (HCC) is one of the most deadly cancers worldwide and has no effective treatment, yet the molecular basis of hepatocarcinogenesis remains largely unknown. Here we report findings from a whole-genome sequencing (WGS) study of 88 matched HCC tumor/normal pairs, 81 of which are Hepatitis B virus (HBV) positive, seeking to identify genetically altered genes and pathways implicated in HBV-associated HCC. We find beta-catenin to be the most frequently mutated oncogene (15.9%) and TP53 the most frequently mutated tumor suppressor (35.2%). The Wnt/beta-catenin and JAK/STAT pathways, altered in 62.5% and 45.5% of cases, respectively, are likely to act as two major oncogenic drivers in HCC. This study also identifies several prevalent and potentially actionable mutations, including activating mutations of Janus kinase 1 (JAK1), in 9.1% of patients and provides a path toward therapeutic intervention of the disease. 
ER  -